ALRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aileron Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $6.89 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. Aileron Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $1.41. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Aileron Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.01.
The historical data trend for Aileron Therapeutics's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aileron Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Total Stockholders Equity | Get a 7-Day Free Trial | 16.05 | 12.16 | 43.90 | 18.62 | 6.89 |
Aileron Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Stockholders Equity | Get a 7-Day Free Trial | 18.62 | 14.27 | 12.79 | 11.20 | 6.89 |
Aileron Therapeutics (NAS:ALRN) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
Aileron Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (6.887 | - | 0) | / | 4.88551 | |
= | 1.41 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
Aileron Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.048 | + | 0) | / | 6.887 | |
= | 0.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Aileron Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
James Brian Windsor | officer: See Remarks | 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746 |
William Fairey | director | C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043 |
Alan A Musso | director | FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Susan L. Drexler | officer: See Remarks | 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462 |
Muneer A Satter | 10 percent owner | C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611 |
Reinhard J. Ambros | director | C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139 |
Von Rickenbach Josef H | director | C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163 |
Jeffrey Allen Bailey | director | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
Vojo Vukovic | officer: SVP, Chief Medical Officer | C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421 |
Kathryn Gregory | officer: SVP, Chief Business Officer | 305 THAYER POND ROAD, WILTON CT 06897 |
William Mckee | director | |
Nolan Howard Sigal | director | 941 BERRY AVENUE, LOS ALTOS CA 94024 |
Novartis Bioventures Ltd | 10 percent owner | C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000 |
Rick Wanstall | officer: VP, Finance and Operations | C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472 |
Longenecker John P Phd | officer: President and CEO | 10445 PACIFIC CENTER CT, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 06-08-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GuruFocusNews GuruFocusNews • 06-18-2022
By GuruFocusNews GuruFocusNews • 06-15-2022
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 06-09-2022
By PurpleRose PurpleRose • 07-15-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.